Study Finds Adults Have Low Serologic Immunity to Hepatitis A and B

The CDC changed hepatitis vaccine recommendations from universal to individual-based for infants in December 2025.

Key Highlights

  • - Only 39.5% of U.S. adults are serologically immune to hepatitis A, and 27.1% to hepatitis B, indicating widespread susceptibility.
  • - Vaccination coverage remains suboptimal, with just 25.2% showing vaccine-derived immunity, highlighting gaps in preventive healthcare.
  • - High-risk groups, including those with liver disease, have lower immunity rates, increasing their vulnerability to hepatitis complications.
  • - The aging of naturally immune cohorts and COVID-19 healthcare disruptions contribute to declining immunity levels among adults.
  • - Infants and young children remain particularly vulnerable, with high rates of chronic disease development if exposed to hepatitis B.

A study published in JAMA Internal Medicine reveals that U.S. adults have low serologic immunity to hepatitis A virus (HAV) and hepatitis B virus (HBV). CIDRAP has the news.

Researchers evaluated HAV and HBV serologic test results from 13,514 adults for the presence of antibodies from previous infection or vaccination. Universal birth-dose HBV vaccination is associated with a 95% reduction in infant HBV infections; the CDC and ACIP, however, recommended individual-based decision-making for infants of mothers without HBV infection in December 2025.

39.5% of adults were serologically immune to HAV, 27.1% had serologic immunity to HBV, and 25.2% showed vaccine-derived immunity. 66.9% of adults were categorized as high-risk. HAV immunity ranged from 26.7% for metabolic dysfunction-linked alcohol-related liver disease to 63.7% for chronic HBV infection. Lower rates of immunity could be explained by the aging of naturally immune cohorts who had HAV in childhood; suboptimal HAV vaccination coverage among younger adults; and COVID-related disruptions to preventive healthcare access.

Infants are also particularly vulnerable to hepatitis; 90% of those exposed to HBV develop chronic disease, compared with 30% of children aged 1 to 5 years and 5% of adults.

About the Author

Matt MacKenzie

Matt MacKenzie

Associate Editor

Matt MacKenzie is Senior Staff Writer and Associate Editor of Healthcare Purchasing News (HPN), where he leads daily news coverage and contributes in-depth features on healthcare supply chain, sterile processing, infection prevention and clinical operations. Through industry reporting and expert interviews, he examines the trends, technologies and operational challenges shaping healthcare purchasing and patient care. 

Sign up for our eNewsletters
Get the latest news and updates